With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition. Both Pliant ...
Hosted on MSN1mon
Pliant stock jumps 28% on bexotegrast study updatePliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical study of bexotegrast in patients with idiopathic pulmonary fibrosis, or ...
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ:PLRX). Investors who purchased Pliant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback